MedTrace Logo

Oncology Treatment Related Ocular Surface Changes

NCT07666724 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2026-06-24

No results posted yet for this study

Summary

clinical trial

The goal of this clinical trial is to learn if drug trastuzumab works to treat HER2 positive mamma carcinomas without causing dry eye related ocular surface changes in adults. The main questions it aims to answer are:

Does trastuzumab increase the dry eye related subjective symptoms? Does trastuzumab cause increased tear film instability and corneal epithelial staining (Oxford score), and lipid layer deterioration? Is a dose-dependent ocular surface effect identifiable attributable to trastuzumab and their modification by patient age?

Participants will:

Take drug trastuzumab-based chemotherapy based on the decision of the local onco-team.

Visit the clinic once every 3 months for checkups and tests Keep a diary of their ocular symptoms Make ocular examination and measure dry eye related parameters

Conditions

  • Breast Neoplasm, Exercise

Interventions

DRUG

Trastuzumab (Herceptin)

trastuzumab treatment as the oncoteam advised

Sponsors & Collaborators

  • Semmelweis University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-18
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07666724 on ClinicalTrials.gov